Concepedia

Chelsea J. Gudgeon

CJ

Statistics

Publications

14

Citations

741

H-Index

13

Active since

2013

Affiliations

University of Washington(Current)

Fred Hutch Cancer Center

Children's Oncology Group

University of Minnesota

University of Southern California

Chelsea J. Gudgeon is an author at University of Washington specializing in oncology, medicine, and acute myeloid leukemia biology.

Publications per year

2013–2022

14

Publications

14

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington et al. · Blood · 2013 · 173 citations · Full text

Life Sciences, Immunology, Oncology +14

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Uwe Reusch, Kimberly H. Harrington, Chelsea J. Gudgeon et al. · Clinical Cancer Research · 2016 · 89 citations · Full text

Pharmacy, Immunology, Oncology +17

T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330

G. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington et al. · Blood Cancer Journal · 2015 · 74 citations · Full text

Medicine, Immunology, Oncology +17

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group

George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon et al. · Journal of Hematology & Oncology · 2015 · 61 citations · Full text

Medicine, Hematology, Oncology +14

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

Kimberly H. Harrington, Chelsea J. Gudgeon, George S. Laszlo et al. · PLoS ONE · 2015 · 61 citations · Full text

Life Sciences, Hematology, Immunology +16

1–5 of 14